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Interleukin-6 (IL-6) is involved in the growth and differentiation of numerous cell types. In the skin it is produced
primarily by keratinocytes. The transcription factor STAT3 is activated by cytokines of the IL-6 family. In this study,
we examined the involvement of IL-6, soluble IL-6-receptor, and STAT3 in epidermal barrier repair after injury to the
stratum corneum by tape-stripping. After barrier disruption in wild-type mice we found an increased immuno-
staining of IL-6 and IL-6R on epidermal keratinocytes at 15 min to 5 h after treatment. The increase in IL-6 and IL-6R
was conﬁrmed by western blotting using epidermal homogenates and was partially prevented by occlusion
immediately after barrier disruption. In IL-6-deﬁcient mice, epidermal barrier repair was reduced at 3–24 h after
treatment. Topical application of IL-6 or Hyper-IL-6, a complex of IL-6 linked to the soluble IL-6 receptor, enhanced
epidermal barrier repair in wild-type mice. Application of the fusion protein gp130-FC, a speciﬁc inhibitor of the
agonist IL-6/sIL-6 receptor complex, delayed barrier repair in wild, but not in IL-6-deﬁcient mice. STAT3 tyrosine
phosphorylation was induced after barrier disruption in wild-type, but markedly reduced in IL-6-deﬁcient mice. Our
results indicate that the IL-6 cytokine system, particularly transsignalling via the soluble IL-6R, is critically involved
in barrier repair after skin injury.
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Cytokines are very important for skin permeability repair.
Previously, it has been shown that after experimental barrier
disruption in mouse and human skin an increase in TNF,
IL-1-a and -b mRNA and protein level occurs (Wood et al,
1992; Nickoloff and Naidu, 1994; Wood et al, 1997). Using
mice strains that are defective in TNF-R1 or in IL-1R1, we
found a delay in skin permeability repair (Jensen et al, 1998;
Jensen et al, 1999). In fibroblasts it has been shown that
TNF and IL-1 stimulate the production of IL-6 (Xiang et al,
1998). In the skin IL-6 is produced primarily by epidermal
keratinocytes, whereas macrophages, Langerhans’ cells,
and fibroblasts in the dermis represent a minor source of
this cytokine (Castella-Rodellas, 1992). In full thickness skin
wounds and after thermal injury of mice IL-6 is produced
locally and released within 30 min after injury; enhanced
levels have been described still 24 h after treatment
(Kawakami et al, 1997; Grellner et al, 2000).
Interleukin-6 (IL-6) is a pleiotropic cytokine that is
involved in the growth and differentiation of numerous cell
types (Audet et al, 2001). Increased levels of IL-6 have been
associated with a number of skin and mucous membrane
pathologies, such as psoriasis (Castells-Rodellas et al,
1992), lupus erythematosus (Nurnberg et al, 1995), or
Sjogren’s Syndrome (Kawasaki et al, 2003). IL-6 first binds
to its membrane bound receptor (IL-6R). Thereupon, the
IL-6/IL-6R complex associates with the gp130 receptor
subunit, followed by homodimerization of gp130 (Groetzin-
ger et al, 1999). Neither IL-6 nor the IL-6R alone bind or
activate gp130. Homodimerization of gp130 causes phos-
phorylation of gp130 and the transcription factors STAT1
and STAT3 by Janus-Kinases (JAK1, JAK2, TYK2), which
are constitutively associated with gp130 (Heinrich et al,
1998). STAT3-dependent gene expression also causes
upregulation of inhibitory proteins of the SOCS family that
interfere with JAK activity (Naka et al, 1997; Starr et al, 1997;
Ernst et al, 2001). Also, STAT3 regulates the migration of
cells, in particular keratinocytes (Hirano et al, 2000) and is
therefore important for wound healing. STAT3/ mice are
not viable, but show early embryonic death. A keratinocyte-
specific ablation of STAT3 in mice led to a reduced wound
healing (Sano et al, 1999).
Interestingly, IL-6 can also associate with the naturally
occurring soluble IL-6R (sIL-6R). The complex of IL-6 and
sIL-6R can thereby activate target cells which do not
express the membrane bound IL-6R. Such cells in the
absence of sIL-6R would not be able to respond to IL-6.
This process has been named ‘‘transsignaling’’ (Rose-John
and Heinrich, 1994). The IL-6/sIL-6R complex may therefore
either potentiate the IL-6 activity on cells expressing the
transmembrane IL-6R (Mackiewicz et al, 1992; Peters et al,
1996; Peters et al, 1998) or widen the array of potential IL-6
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targets to cells devoid of the transmembrane IL-6R (Jones,
2001; Jones and Rose-John, 2002). Since all human cells
express gp130 on the cell surface, the IL-6/sIL-6R complex
can principally activate all body cells. In recent years,
increasing attention has therefore been directed to the role
of the sIL-6R in human diseases (Jones, 2001; Jones and
Rose-John, 2002; Kallen, 2002). Two engineered fusion
proteins have helped to elucidate the biology of the sIL-6R.
The designer cytokine Hyper-IL-6, which covalently links
IL-6 with the sIL-6R (Fischer et al, 1997), shows a much
higher activity on cells than the IL-6/sIL-6R complex. A
recently cloned fusion protein of the extracellular domains
of gp130 with the constant region of the heavy chain of
human IgG1, gp130-Fc, has been shown to specifically
inhibit processes mediated via the sIL-6R, but not those
relayed by the membrane bound IL-6R (Atreya, 2000; Hurst
et al, 2001; Jostock et al, 2001). Using IL-6-deficient mice,
Hyper-IL-6 and gp130-Fc we have analyzed the role of the
IL-6 cytokine system in skin barrier repair. We show that IL-6
accelerates barrier repair and that this effect seems to be
mainly mediated via the sIL-6R.
Results
IL-6 and IL-6R are induced in murine skin in all
nucleated layers after injury by tape-stripping occlu-
sion The cell-specific localization of cytokines is important
for their functions. We investigated the localization of IL-6
and IL-6R in murine skin before and after skin permeability
barrier disruption immunohistochemically using specific
antibodies (Fig 1). As has been described previously in
human skin (reviewed in Gallucci et al, 2000) we found little
staining for IL-6 and IL-6R on fibroblasts or lymphocytes.
Instead IL-6 and IL-6R were visible on keratinocytes. In
unperturbed epidermis we found faint staining on keratino-
cytes in the basal, granular, and horny layers, but not in the
spinous layers. Fifteen min after skin barrier disruption by
tape-stripping staining of basal and stratum granulosum
keratinocytes was clearly visible. Also, some suprabasal
keratinocytes in the spinous layers were stained. With time,
staining intensity increased and reached the highest levels
for IL-6 and for IL-6R at 1–3 h after treatment. At these
points in time, staining was equally distributed in the entire
nucleated epidermis. Thereafter, staining intensity was
reduced, at 5 h the basal layer was devoid of cytokine/
receptor staining (IL-6: Fig 1a–e, IL-6R: Fig 1g–k). These
findings demonstrate that IL-6 and IL-6R are localized to
keratinocytes in mouse skin, and that their expression
increases after skin barrier disruption.
After occlusion by a Latex foil following barrier disruption,
an increase in staining for IL-6 and IL-6R was still detectable
3 h after treatment. Staining for IL-6 and especially for IL-
6R, however, was reduced and concentrated in the outer
nucleated epidermal layers (Fig 1f and l).
We carried out additional western blotting of epidermal
samples and found nearly 2-fold increased levels for IL-6 at
1 h and for IL-6R at 3 h after barrier disruption (Fig 2a and b).
Delayed permeability barrier repair in IL-6-deﬁcient
mice. Reversed delay by topical application of IL-6 To
evaluate the possible involvement of IL-6, we examined
barrier repair in IL-6-deficient mice after tape-stripping. As
shown in Fig 3, IL-6-deficient mice exhibited a significant
delay in barrier repair at 3–24 h after treatment. The delay in
barrier repair peaked at 7 h (25% reduced recovery;
po0.005, n¼5). The delay in permeability barrier repair was
reversed by topical application of 3 mg of recombinant IL-6
in a volume of 30 mL (barrier recovery at 1h: IL-6 def. 20%,
IL-6 def.þ IL-6 26%, wild-type 30%; 3h: IL-6 def. 29%, IL-6
def.þ IL-6 59%, wild-type 41%; 5h: IL-6 def. 45%, IL-6
Figure1
Immunohistochemical staining of IL-6 and IL-6R is increased and
localized to all nucleated epidermal layers after barrier disruption.
Disruption of the permeability barrier was induced on one flank of wild-
type mice by tape stripping. At different time points after treatment,
skin samples were obtained and cryostat sections were incubated with
anti-IL-6 and anti-IL-6R antibodies. Note that IL-6 and IL-6R was
induced first in the basal layer (15 min) and then in the entire nucleated
epidermis (1 and 3 h). Thereafter, cytokine staining was reduced,
especially in the basal layer (5 h). Occlusion with a Latex foil, shown at
3 h, reduced IL-6 and IL-6R compared with unoccluded skin. (Also
reduced thickness of the SC after tape-stripping is clearly visible).
Scale bar¼30 mm.
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def.þ IL-6 65%, wild-type 55%; 24h: IL-6 def. 72%, IL-6
def.þ IL-6 85%, wild-type 77%). Although this data indi-
cate, that IL-6 plays an important role in barrier repair, it
does not clarify whether the IL-6 effect in barrier repair of
the skin was mediated via the membrane bound or the
soluble IL-6R (see below).
Topical application of IL-6 or Hyper-IL-6-enhanced
permeability barrier repair Repeated tape-stripping of
the skin removed cells from the stratum corneum and
resulted in a superficial wound. As a marker of barrier
disruption, we determined an increase in TEWL from
1.8  0.2 to 45.0  15.3 g per m2 per h. Immediately after
treatment barrier repair commenced, a rapid decrease in
TEWL leading to about 60% barrier recovery occurred in
hairless mice within 7 h. This was followed by slower
kinetics of barrier recovery within 24 h (Fig 4). To further
investigate the possible involvement of IL-6 in barrier repair,
the cytokine was applied topically immediately after barrier
disruption at different concentrations. IL-6 at a concentra-
tion of 100 ng per mL (30 mL applied in total) significantly
enhanced permeability barrier repair 1–7 h (20% at 7 h) after
treatment compared with the vehicle-treated control
(po0.01, n¼ 4). A slight but not significant enhancement
in barrier repair also occurred after topical application at a
low concentration of 10 ng per mL 3, 5, and 7 h after treat-
ment. The high concentration of 1000 ng per mL led to a signi-
ficant enhancement at 1h (po0.01, n¼4). These results
show that topically applied IL-6 is able to enhance perme-
ability barrier repair in a concentration-dependent manner.
Topical application of Hyper-IL-6 also enhanced skin
permeability barrier repair. At a concentration of 100 ng per
mL, we found a significant enhancement 1–24 h after
treatment (Fig 5). A low concentration of 10 ng per mL led
to a slight (but not significant) enhancement in barrier repair
after 1 h. At a high concentration of 1000 ng per mL, Hyper-
IL-6 enhance the barrier at 1 h. We also induced barrier
disruption with acetone and applied 100 ng per mL Hyper-
IL-6 and got results similar to tape-stripping-induced barrier
disruption (not shown). This demonstrates that Hyper-IL-6
also improved permeability barrier repair. Hyper-IL-6, how-
ever, did not show higher activity in barrier repair than IL-6.
Topical application of gp130-Fc delayed permeability
barrier repair in wild-type mice, but not in IL-6-deﬁcient
mice To further clarify whether the IL-6 effect on barrier
repair depended on the membrane bound or the soluble IL-
6R, the gp130-Fc fusion protein, specific inhibitor of trans-
signalling via the sIL-6R, was topically applied to the skin of
hairless mice after tape-stripping. In contrast to IL-6 or
Hyper-IL-6, gp130 significantly delayed barrier repair at
1–24 h (Fig 6).
Topical application of gp130-Fc in IL-6-deficient mice did
not significantly delay the already reduced barrier repair in
IL-6-deficient mice examined after tape-stripping (barrier
recovery at 1h: IL-6 def. 20%, IL-6 def.þgp130 14%; 3h:
IL-6 def. 29%, IL-6 def.þgp130 30%; 5h: IL-6 def. 45%, IL-
6 def.þgp130 50%; 24h: IL-6 def. 72%, IL-6 def.þgp130
65%). These results shows that gp130 is able to retard the
skin repair process in wild-type mice after superficial
wounding, indicating an involvement of sIL-6R in the
process of skin repair.
STAT3 protein is phosphorylated after skin barrier
disruption in wild-type and less pronounced in IL-6-
deﬁcient mice To further substantiate the role of the IL-6-
Figure 2
Increased levels for IL-6 and IL-6R are also noted by western
blotting. We also carried out western blotting and, as already shown by
immunohistochemistry, we found increased levels of IL-6 1 h (NS) and
increased levels of IL-6R 3 h after barrier disruption (po0.01,
mean  SEM, n¼ 4) (Fig 2a and b).
Figure3
Skin permeability barrier repair is delayed in IL-6-deficient mice. In
IL-6-deficient mice and wild-type control mice, disruption of the
permeability barrier was induced by tape stripping. TEWL as a marker
of barrier function was monitored immediately after treatment and at
several time points for 24 h. Recovery in barrier function as indicated by
a reduction in TEWL was significantly reduced 3–24 h after skin injury
(po0.05, n¼4).
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dependent signaling pathway in barrier repair, we examined
whether STAT3 was activated (i.e., phosphorylated) during
permeability barrier repair. After skin injury by tape-stripping
we examined the phosphorylation of STAT3 in the epidermis
using western immunoblots. STAT3 phosphorylation was
low in untreated epidermis, but significantly increased 1h
after tape-stripping (Fig 7). This shows that the transcription
factor STAT3, which is induced by IL-6-mediated gp130
dimerization, is activated during skin barrier repair.
In IL-6-deficient mice, STAT3 phosphorylation was
markedly reduced, but not completely absent compared
with wild-type mice (Fig 7). This may suggest that IL-6 is an
important though not sole regulator of STAT3 phosphoryla-
tion in the skin.
Discussion
In this study, we found that the IL-6 and IL-6R proteins are
preferentially localized in low amounts in the skin of hairless
mice under basal conditions to keratinocytes in the basal,
granular, and horny layers, but not in the spinous layers of
the epidermis (Fig 1a and g). In the dermis we found little
staining by IL-6 and the IL-6R antibodies on fibroblasts, and
a lack of staining on other cells in the skin. Preferred
localization of IL-6 to keratinocytes in the skin has been
described previously in human skin (Paquet and Pierard,
1996). Within the epidermal keratinocytes, localization to
the basal proliferating compartment, but not to the upper
differentiated cell layers in human keratinocyte culture has
also been reported (Yoshizaki et al, 1990; Castella-Rodellas
et al, 1992).
After experimental barrier disruption by tape-stripping,
an increase for IL-6 and IL-6R in a time-dependent manner
was noted. Fifteen min after treatment, staining of basal and
stratum granulosum keratinocytes and some suprabasal
keratinocytes in the spinous layers was visible. Staining
intensity increased and reached the highest levels for IL-6
and IL-6R at 1–3 h after treatment. IL-6 and IL-6R were
equally distributed in the entire nucleated epidermis.
Thereafter, staining intensity was reduced. After 5 h the
basal layer was devoid of the cytokine/receptor (Fig 1a–e
and g–k).
We also carried out western blotting and, as already
shown by immunohistochemistry, we found increased levels
for IL-6 1 h and increased levels for IL-6R 3 h after barrier
disruption (Fig 2a and b). These findings are in accordance
Figure 4
Topical application of IL-6 enhanced, in a concentration-depen-
dent manner, permeability barrier repair in wild-type mice.
Immediately after skin barrier disruption, IL-6 was topically applied in
different concentrations to the skin of wild-type mice. Barrier recovery
after the application of IL-6 (100 ng per mL) was monitored by a
reduction of TEWL for 24 h (Fig 4a). The dose–response of barrier
recovery in relation to control is shown in Fig 4b. Note that barrier repair
was significantly enhanced by IL-6 1–7 h after treatment at a
concentration of 100 ng per mL, and after 1 h at a concentration of
1000 ng per mL (po0.05, n¼4).
Figure5
Topical application of Hyper-IL-6-enhanced permeability barrier
repair in wild-type mice. The study was performed as described for
Fig 4 (Fig 5a). The dose–response of barrier recovery in relation to
control is shown in Fig 5b. Note that barrier repair was significantly
enhanced by Hyper-IL-6 3–24 h after treatment at a concentration of
100 ng per mL, (po0.05, n¼ 4).
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with published mRNA studies using the sensitive RNase
protection assays. Wood et al (1997) reported an increase in
IL-6 mRNA after barrier disruption. There are small
differences, however, regarding the time curve. Wood et al
found an increase in mRNA levels only 2.5 h after barrier
disruption. We found that the time curve for barrier repair
depends on the degree of barrier disruption. After severe
barrier disruption the time curve for barrier regeneration is
delayed because of the toxicity to the cells induced by
vigorous treatments with acetone, SDS, or tape-stripping. In
these studies we carefully disrupted the barrier. In accor-
dance with our results Kawakami et al described increased
IL-6 levels in the skin 30 min after thermal injury in mice
(Kawakami et al, 1998).
Elevated levels for IL-6 and IL-6R still occurred after
occlusion by a Latex foil following barrier disruption.
Compared with unoccluded skin staining was slightly
reduced (1f and l). Similarly, Wood et al reported that
occlusion did not significantly modify the increased expres-
sion of TNF and IL-1 after barrier disruption (Wood et al,
1997). Warner et al very recently described that hyper-
hydration by application of an occlusive patch test chamber
in human skin in vivo disrupts human stratum corneum
ultrastructure already 4 h after treatment (Warner et al,
2003). Also, it is common knowledge in clinical dermatology
that application of occlusive foils in acute dermatitis does
not reduce, but may rather enhance inflammation, because
occlusion hinders heat emission. Therefore, it is reasonable
that occlusion after barrier disruption may reduce but not
totally prevent the increase in inflammation-related cyto-
kines TNFa, IL-1, and IL-6.
In IL-6-deficient mice we determined a significant delay
in permeability barrier repair after 1–24 h (Fig 3). Previously,
it has been published that TNFa and IL-1b stimulate the
production of IL-6 fibroblasts (Xiang et al, 1998). It is of
interest to compare the effects of TNFa and IL-1b with the
effects of IL-6 on barrier repair in the mice in vivo. We
previously examined skin permeability barrier repair in TNF-
R1 and in IL-1R-1-deficient mice. In TNF-R1-deficient mice
we found a significant delay in the repair process 1, 3, and
5 h after tape-stripping (Jensen et al, 1999). In IL-1R1-
deficient mice the repair was only slightly reduced and did
not reach statistical significance (Jensen et al, 1998). As
shown in this study, a deficiency in IL-6 caused a more
pronounced reduction in barrier repair than a deficiency in
either TNFa or IL-1b. This is in line with other studies, which
suggest that IL-6 appears to act as a downstream effector
of TNFa and IL-1b in many experimental systems (Kallen
et al, 1999a).
Topical application of IL-6 to barrier-disrupted skin
enhanced the skin barrier repair in a concentration-
dependent manner. A significant effect was found with a
concentration of 100 ng per mL, where enhanced repair was
found 1, 3, 5, and 7 h after treatment. At a low concentration
of 10 ng per mL there was a tendency to increased barrier
repair only. The high concentration of 1000 ng per mL IL-6-
enhanced barrier repair only at 1 h after treatment (Fig 4). A
bell-shaped curve of IL-6 concentration-dependency with
decreased activity at higher doses has been described in
the past (Aarden, 1989; van Dam et al, 1993) and has been
explained by a transition from an active tetrameric to an
inactive hexameric receptor complex (Groetzinger et al,
1999). This mechanism could be the basis of the dose
effects observed here. Again, we were interested in
comparing the effects of IL-6 with TNFa and IL-1b in the
same system in vivo. We previously performed topical
application of TNFa and IL-1b to mouse skin after barrier
disruption. TNFa as well as IL-1b led to an increase in
barrier repair 1, 3, and 5 h after tape-stripping. Topical
application of IL-6, however, was more effective than either
TNFa or IL-1b. Topical application of IL-6 was also effective
in IL-6-deficient mice. The delay in permeability barrier
repair was reversed by topical application of the cytokine
down to levels similar to vehicle treated wild-type mice.
Like IL-6, Hyper-IL-6-enhanced permeability barrier
repair. As with IL-6 the effect was highly significant with a
concentration of 100 ng per mL, whereas, with a low (10 ng
per mL) concentration there was only a tendency (n.s.) for an
increased barrier repair. At a high concentration (1000 ng
per mL) Hyper-IL-6-enhanced permeability barrier repair
only 1 h after treatment (Fig 5). Again, this might reflect
Figure 6
Topical application of gp130 delayed permeability barrier repair in
wild-type mice. The study was performed as described for Fig 3. Note
that barrier repair was significantly reduced 1–24 h after topical
application of gp130 (po0.05, n¼ 4).
Figure 7
Phosphorylation of STAT3 was induced during skin permeability
barrier repair in wild-type and much less in IL-6-deficient mice.
Expression of STAT3 phosphorylated protein was low in untreated
epidermis, but significantly increased 1 h after barrier disruption. In
wild-type mice, we found a 4-fold, in IL-6-deficient mice a 2-fold
increase in STAT3 (n¼2).
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transition from an active tetrameric to an inactive hexameric
complex (Groetzinger et al, 1999). This concept has recently
been forwarded to explain the concentration-dependent
effects of Hyper-IL-6 on embryonic stem cells (Viswanathan
et al, 2002).
Acceleration of barrier repair after topical application of
IL-6 occurred within 1 h of treatment, this is in accordance
with our time curve for the induction of IL-6 after barrier
disruption. Again, according to our experience the time
curve for barrier regeneration depends on the degree of
disruption and this also includes epidermal lipogenesis.
Previously, we found an increase in epidermal HMG-CoA
reductase, the rate-limiting enzyme of cholesterol synthesis,
already 1.5 h after barrier disruption (Proksch et al, 1991).
This does not differ much from the here reported increase in
IL-6 levels and enhancement in barrier repair at 1 h after
treatment. Therefore, besides proliferation and differentia-
tion (Audet et al, 2001), IL-6 may be involved in the
regulation of cholesterol synthesis (Kaul, 2001). Epidermal
cholesterol synthesis is important for barrier repair (Gru-
bauer et al, 1987; Proksch et al, 1991).
Topical application of gp130-Fc caused a significant
delay in permeability barrier repair at 1–7 h after treatment.
This indicates strongly that the presence of the sIL-6R is
required for the effect of IL-6 in barrier repair, since gp130-
Fc specifically inhibits effects mediated via the sIL-6R but
not those via the membrane bound receptor (Jostock et al,
2001). Since Hyper-IL-6 was not more effective than IL-6 in
enhancing barrier repair, an obvious conclusion is that local
concentrations of IL-6 and sIL-6R are sufficient to maxi-
mally activate relevant target cells (Jones and Rose-John,
2002).
We have demonstrated the specificity of the delay in
barrier repair with gp130 by applying this compound to IL-6-
deficient mice. We found that the slow repair in barrier
function in IL-6-deficient mice was not significantly affected
by topical application of gp130.
STAT-3 phosphorylation was significantly enhanced 1 h
after permeability barrier disruption. This is in agreement
with the fast induction of IL-6, which we already found
increased 15 min after treatment. We also determined
STAT3 phosphorylation in IL-6-deficient mice. The increase
in STAT3 phosphorylation after barrier disruption was
reduced in comparison with wild-type mice, although an
increase in STAT3 phosphorylation occurred in IL-6-defi-
cient mice (Fig 7). This shows that the IL-6 system is an
important (Ernst et al, 2001), but not the only regulator of
STAT3 phosphorylation. Possible candidates for this effect
are all known gp130 family members (IL-6, IL-11, LIF, CNTF,
OSM, CT-1, ClC) which are known to act as activators of
STAT3 (Choi et al, 2003). Moreover, IL-10 and leptin have
been shown to induce STAT3 activity (Fedorcsak and
Storeng, 2003; Ziegler-Heitbrock et al, 2003). STAT3
phosphorylation has also been described as a conse-
quence of EGFR stimulation (Sriuranpong et al, 2003).
In this study, we showed that the IL-6 system is pivotally
involved in epidermal permeability barrier repair. Impor-
tantly, our study indicates that the sIL-6R rather than the
membrane bound IL-6 receptor seems to be important for
barrier repair (Sano et al, 1999; Hirano et al, 2000). Although
an important pathophysiological function of the sIL-6R has
so far been described in Crohn’s disease, our study is the
first to ascribe a physiological function to the sIL-6R in the
skin. So far, the only physiological role of the sIL-6R
identified is its role in the transition from innate to adaptive
immunity (Hurst et al, 2001). IL-6 and potentially Hyper-IL-6
may be useful to treat barrier disrupted skin such as
eczema and to enhance reepithelization in wound healing.
On the other hand, gp130-Fc may be a useful therapeutic
agent to ameliorate IL-6-mediated diseases like psoriasis,
lupus erythematosus, or Sjogren’s syndrome (Kawasaki
et al, 2003), where the sIL-6R might play a similarly
important role as in Crohn’s disease (Atreya, 2000) and in
peritonitis (Hurst et al, 2001).
Materials and Methods
Animals and materials Male hairless mice [Skh1: (hr/hr) BR]
6–8-wk old, were purchased from Charles River Wiga Laboratories
(Sulzfeld, Germany). IL-6-deficient mice (hrþ /þ ) were generated
by gene targeting (Wuestefeld et al, 2003). IL-6-deficient mice
(hrþ /þ ) were bred on a hairy background, as hairless animals
(hr/hr) were not available. Therefore, the respective wild-type
(hrþ /hrþ ) mice were used as controls. The animals were
maintained conventionally under standardized conditions in groups
in plastic cages with polyester filter covers. The study protocols
were approved by the University of Kiel, Committee of Animal
Care.
Biochemicals were purchased from Sigma-Aldrich Chemistry
(Munich, Germany). The anti-phospho STAT3 antibody was obtaind
from NEB (Bad Schwalbach, Germany). IL-6, Hyper-IL-6 and
gp130-Fc were produced as described recently (Fischer et al,
1997; Kallen et al, 1999b; Jostock et al, 2001).
Experimental procedures
Skin injury and monitoring of epidermal barrier repair Skin injury
and disruption of the permeability barrier were induced in hairless
mice on one flank by tape stripping (cellophane tape, Scotch type,
six to eight times) or by applying acetone-soaked cotton balls until
a 20–30-fold increase in TEWL, a marker for skin barrier function
and SC integrity, was achieved using an electronic water analyzer
(Meeco Instruments Corp., Warrington, Pennsylvania, USA). In
some animals skin was immediately occluded with a water-vapor
impermeable latex foil for 3 h. To assess the kinetics of skin barrier
repair, TEWL was monitored for 24 h after skin injury at several time
points as indicated in the figures. In the hairy IL-6-deficient mice,
the fur was carefully removed using a shaver before barrier
disruption. The shaving did not result in irritation. At different time
points after treatment (0–24 h), skin samples of measuring
approximately 4 cm2 were obtained.
Topical application of IL-6, Hyper-IL-6, and gp130 to wild-type and
IL-6-deﬁcient mouse skin Immediately after SC injury a single
topical application of 30 mL of different concentrations (10–1000 ng
per mL) of IL-6, Hyper-IL-6, or gp130 in isopropanol/propylene
glycol (3:7, vol/vol) was performed in wild-type and in IL-6-deficient
mice. Vehicle application served as control. TEWL was determined
1, 3, 5, 7, and 24 h after treatment.
Immunostaining for IL-6 and IL-6R in skin sections Murine skin
samples were fixed in liquid nitrogen. Cryostat sections were
placed on slides and fixed in acetone for 10 min at room
temperature. Five mm thick cryostat sections were incubated with
0.6% H2O2 for 5 min to block endogenous peroxidase activity and
then rinsed with distilled water. After blocking non-specific
antibody binding by incubation with 20% normal rat serum for 20
min at room temperature, the primary antibodies anti-IL-6 (1:100)
and anti-IL-6R (1:100) (G18402D, BD Bioscience, Germany) were
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applied for 30 min at room temperature. A StreptABComplex/HRP
was used as second antibody for 30 min at room temperature,
followed by incubation with diaminobenzidine as peroxidase
substrate.
Western blotting for IL-6, IL-6-receptor, and STAT3 phosphoryla-
tion Disruption of the permeability barrier in hairless mice and
application of Hyper-IL-6 was performed as described above. Skin
samples were collected, minced and frozen in liquid nitrogen. The
skin was homogenized in 400 mL H-buffer (40 mM Hepes, 150 mM
KCl, 5 mM NaF; pH 7.4) for 30 s. Especially for STAT-3-P detection
homogenates were sonicated three times for 10 s in the cold. By
centrifugation at 13,800 g at 41C for 20 min debris was removed.
The amount of soluble proteins in the supernatants were
assigned by BCA method. Twenty-five mg protein were used for
SDS-PAGE (10% Tris–Ticine gel) and western blot analysis.
Precision plus protein marker (BioRad 161-0373) was run parallel
as a standard. Sample and standard solutions were mixed in
sample buffer (50 mM Tris, 4 M urea, 1% SDS, 15% glycerol,
0.01% bromophenol blue, 9% mercaptoethanol; pH 6.8) and
heated to 95 1C for 5 min as required for electrophoresis (La¨mmli,
1970). Separated proteins were blotted to nitrocellulose membrane
(Schleicher and Schuell (Germany) GB 002) for 45 min and 100 V in
cold blotting buffer (25 mM Tris, 192 mM glycin, 20% methanol; pH
8.3).
Non-specific antibody binding was inhibited by incubation of
the membrane with 5% milk powder in Tris-buffered saline T (Tris
buffer, 0.1% Tween-20; pH 7.4). The following staining protocol
was used: As primary antibody, the polyclonal rabbit anti-phospho-
STAT3 antibody Y705 (upstate biotechnology), the biotin conju-
gated monoclonal rat anti-IL-6 antibody (Pharmingen 554399) or
the rat anti-IL-6-receptor antibody (Pharmingen 554461) was used,
respectively, overnight at 41C under rotation, diluted 1:500–1000
(vol/vol) in TBST buffer with 2% milk powder as blocking reagent.
Next a 1:1000 (vol/vol) diluted biotin conjugated swine anti-rabbit
antibody (DAKO E0353) in case of STAT3 was used for 1 h. To
amplify the detection of STAT-3-P, IL-6 and IL-6-R the membrane
was further incubated with horseradish peroxidase coupled
StreptABComplex/HRP (Dako Diagnostica, 1:100, vol/vol) for 1 h.
Between all incubation steps the membrane was washed three
times with TBST buffer for 5 min at room temperature under
shaking. The expression of STAT-3-P, IL-6 and IL-6-R was detected
with the ECL detection system (Amersham RPN 2209).
Statistical Analyses
Statistics Statistical significance was determined using the ANOVA
test. Each sample was measured in duplicate and the results are
presented as the mean  SEM.
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